Healthtech startup Corti today announced the launch of the Startup Acceleration Program, a no-equity initiative providing healthcare AI builders worldwide with access to the same clinical-grade models that power AI for highly regulated systems across Europe and the US. The grant-funded program aims to help founders ship and scale at a moment when the regulatory bar for healthcare AI has never been higher.
Check out our earlier interview with Andreas Cleve, CEO and co-founder of Corti.
Copenhagen-headquartered Corti offers healthcare a frontier lab for clinical-grade AI. Symphony, its flagship clinical-grade AI model, powers clinical and administrative applications for EHR vendors, virtual care platforms, practice management systems, and life sciences organisations worldwide. It serves over 100 million patients annually across health systems, including the NHS.
Symphony has outscored OpenAI on HealthBench Professional, the company’s new healthcare benchmark. Healthcare AI builders now face tightening regulation in every major market - from the FDA's expanded AI/ML guidance in the US to new lifecycle accountability requirements in Canada and the UK.
But Europe is the most acute case. In the past four weeks, OpenAI rolled out free clinical AI to every verified American physician. One week later, OpenEvidence — a clinical AI platform used daily by 40 per cent of US physicians and valued at $12 billion — withdrew from the UK and European markets, citing regulatory uncertainty around the EU AI Act.
